Targeting CDK4/6 for Anticancer Therapy

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Mar 25

PMID 35327487

Authors

Jiating Qi

Zhuqing Ouyang

Affiliations

Soon will be listed here.

Abstract

Cyclin-dependent kinase 4/6 (CDK4/6) are key regulators of the cell cycle and are deemed as critical therapeutic targets of multiple cancers. Various approaches have been applied to silence CDK4/6 at different levels, i.e., CRISPR to knock out at the DNA level, siRNA to inhibit translation, and drugs that target the protein of interest. Here we summarize the current status in this field, highlighting the mechanisms of small molecular inhibitors treatment and drug resistance. We describe approaches to combat drug resistance, including combination therapy and PROTACs drugs that degrade the kinases. Finally, critical issues and perspectives in the field are outlined.

Citing Articles

A Two-Sample Mendelian Randomization Study of Basophil Count and Risk of Gestational Diabetes Mellitus.

Mao J, Gan Y, Tan X, He Y, Jing Q, Shi Q Int J Womens Health. 2025; 17:517-527.

PMID: 40028461 PMC: 11872098. DOI: 10.2147/IJWH.S500632.

The interplay of p16INK4a and non-coding RNAs: bridging cellular senescence, aging, and cancer.

Balaraman A, Afzal M, Moglad E, Babu M, Priya G, Bansal P Biogerontology. 2025; 26(2):50.

PMID: 39907830 DOI: 10.1007/s10522-025-10194-2.

Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling.

Yang L, Yue Y, Wang Z, Jiang Y, Xue Z, Zhang Y Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852139 PMC: 11763656. DOI: 10.3390/cimb47010024.

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer.

Mughal M, Zhang Y, Li Z, Zhou S, Peng C, Zhang Y Cancer Lett. 2024; 610:217356.

PMID: 39603379 PMC: 11783577. DOI: 10.1016/j.canlet.2024.217356.

Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials.

Apostolidou K, Zografos E, Papatheodoridi M, Fiste O, Dimopoulos M, Zagouri F Breast. 2024; 75:103729.

PMID: 38599049 PMC: 11011217. DOI: 10.1016/j.breast.2024.103729.

References

Kettner N, Vijayaraghavan S, Guray Durak M, Bui T, Kohansal M, Ha M . Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019; 25(13):3996-4013. PMC: 6606366. DOI: 10.1158/1078-0432.CCR-18-3274. View

Li C, Liu L, Liang L, Xia Z, Li Z, Wang X . AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia. Mol Cancer Ther. 2014; 14(2):375-83. DOI: 10.1158/1535-7163.MCT-14-0388. View

Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G . A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010; 18(1):63-73. DOI: 10.1016/j.ccr.2010.05.025. View

Rader J, Russell M, Hart L, Nakazawa M, Belcastro L, Martinez D . Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 19(22):6173-82. PMC: 3844928. DOI: 10.1158/1078-0432.CCR-13-1675. View

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian C, Roberto M . Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2016; 66(7):1286-1296. PMC: 5512174. DOI: 10.1136/gutjnl-2016-312268. View

Corona S, Generali D . Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther. 2018; 12:321-330. PMC: 5818877. DOI: 10.2147/DDDT.S137783. View

Sheppard K, McArthur G . The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013; 19(19):5320-8. DOI: 10.1158/1078-0432.CCR-13-0259. View

Goel S, Wang Q, Watt A, Tolaney S, Dillon D, Li W . Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016; 29(3):255-269. PMC: 4794996. DOI: 10.1016/j.ccell.2016.02.006. View

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

10.

Gorgoulis V, Adams P, Alimonti A, Bennett D, Bischof O, Bishop C . Cellular Senescence: Defining a Path Forward. Cell. 2019; 179(4):813-827. DOI: 10.1016/j.cell.2019.10.005. View

11.

Li Y, Jiang F, Shi X, Liu X, Yang H, Zhang Z . Identification and Characterization of the Cyclin-Dependent Kinases Gene Family in Silkworm, Bombyx mori. DNA Cell Biol. 2015; 35(1):13-23. DOI: 10.1089/dna.2015.3049. View

12.

Purba T, Ngandu K, Brunken L, Smart E, Mitchell E, Hassan N . CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia. EMBO Mol Med. 2019; 11(10):e11031. PMC: 6783643. DOI: 10.15252/emmm.201911031. View

13.

Yuan K, Wang X, Dong H, Min W, Hao H, Yang P . Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharm Sin B. 2021; 11(1):30-54. PMC: 7838032. DOI: 10.1016/j.apsb.2020.05.001. View

14.

Johnson S, Torrice C, Bell J, Monahan K, Jiang Q, Wang Y . Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest. 2010; 120(7):2528-36. PMC: 2898594. DOI: 10.1172/JCI41402. View

15.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C . Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018; 34(6):893-905.e8. PMC: 6294301. DOI: 10.1016/j.ccell.2018.11.006. View

16.

Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z . eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. Mol Cancer Ther. 2019; 18(11):2158-2170. PMC: 7132330. DOI: 10.1158/1535-7163.MCT-19-0162. View

17.

OBrien N, McDermott M, Conklin D, Luo T, Ayala R, Salgar S . Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 2020; 22(1):89. PMC: 7427086. DOI: 10.1186/s13058-020-01320-8. View

18.

Vilgelm A, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen S . MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Sci Transl Med. 2019; 11(505). PMC: 7584132. DOI: 10.1126/scitranslmed.aav7171. View

19.

Su S, Yang Z, Gao H, Yang H, Zhu S, An Z . Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019; 62(16):7575-7582. PMC: 6790125. DOI: 10.1021/acs.jmedchem.9b00871. View

20.

Li J, Xu M, Yang Z, Li A, Dong J . Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Invest. 2009; 28(4):350-6. DOI: 10.3109/07357900903286966. View